Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Rivaroxaban (Xarelto -- Bayer Inc.) indication : coronary artery disease with or without peripheral artery disease

The CADTH Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be reimbursed in combination with acetylsalicylic acid (ASA; 75 mg to 100 mg) for the prevention of stroke, myocardial infarction, and cardiovascular death, and for the prevention of acute limb ischemia and mortality in pati...

Full description

Bibliographic Details
Corporate Author: CADTH Canadian Drug Expert Committee
Format: eBook
Language:English
Published: Ottawa (ON) CADTH 2018, November 2018
Edition:Final
Series:CADTH common drug review
Subjects:
Insurance, Health, Reimbursement
Stroke / Prevention & Control
Canada
Aspirin
Secondary Prevention
Rivaroxaban / Economics
Rivaroxaban / Therapeutic Use
Coronary Artery Disease / Drug Therapy
Cost-benefit Analysis
Myocardial Infarction / Prevention & Control
Ischemia / Prevention & Control
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02007nam a2200397 u 4500
001 EB001888670
003 EBX01000000000000001052031
005 00000000000000.0
007 tu|||||||||||||||||||||
008 200106 r ||| eng
245 0 0 |a CADTH Canadian Drug Expert Committee recommendation: Rivaroxaban (Xarelto -- Bayer Inc.)  |h Elektronische Ressource  |b indication : coronary artery disease with or without peripheral artery disease 
246 3 1 |a Rivaroxaban (Xarelto -- Bayer Inc.) 
246 3 1 |a Drug reimbursement recommendation Rivaroxaban (Xarelto) 
250 |a Final 
260 |a Ottawa (ON)  |b CADTH  |c 2018, November 2018 
300 |a 1 PDF file (7 pages) 
653 |a Insurance, Health, Reimbursement 
653 |a Stroke / prevention & control 
653 |a Canada 
653 |a Aspirin 
653 |a Secondary Prevention 
653 |a Rivaroxaban / economics 
653 |a Rivaroxaban / therapeutic use 
653 |a Coronary Artery Disease / drug therapy 
653 |a Cost-Benefit Analysis 
653 |a Myocardial Infarction / prevention & control 
653 |a Ischemia / prevention & control 
710 2 |a CADTH Canadian Drug Expert Committee 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK541456  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 700 
082 0 |a 610 
082 0 |a 330 
520 |a The CADTH Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be reimbursed in combination with acetylsalicylic acid (ASA; 75 mg to 100 mg) for the prevention of stroke, myocardial infarction, and cardiovascular death, and for the prevention of acute limb ischemia and mortality in patients with concomitant coronary artery disease (CAD) and peripheral artery disease (PAD) if the following condition is met: For patients with concomitant CAD and PAD as defined in the Implementation Considerations 

Similar Items